secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-06-02T23:59:59+00:00
Accession:  0001564590-22-022228
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon shareholders approve 5.3M share equity plan increase; all director nominees elected
--------------------------------------------------------------------------------

- Amendment to 2014 Equity Plan approved: 35.6M for, 6.2M against, 5.1M broker non-votes.
- Total share reserve under plan increased to ~13.37M shares (includes prior reserves and 5.3M addition).
- All eight director nominees elected with strong majority (e.g., Simon Pimstone 40.9M for).
- Say-on-pay advisory vote passed: 41.1M for, 0.6M against.
- KPMG reappointed as auditor with 45.9M for, 1.0M withheld.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022022228/0001564590-22-022228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022022228/xene-8k_20220601.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-022228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer